Related Experiment Video
Updated: Apr 25, 2026

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation
Chris G Yedinak1, Shirley McCartney1, Troy H Dillard2
1Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Abstract:
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild valvulopathy. Valvulopathy was subsequently reversed after discontinuation of cabergoline therapy.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Desensitization and Tachyphylaxis
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: β-Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...

